Fairvalue-Calculator Fairvalue-Calculator
EN DE

Xvivo Perfusion AB (XVIPF) Fair Value & Analysis

Healthcare · US · Market cap $914M

Price$29.00
Fair Value$3.43
Upside-88.2%
Quality95/100
Evidence: Medium Range $2.40 – $3.43

Fair value as of: Jun 25, 2026

Analysis

Xvivo Perfusion AB (XVIPF) currently trades at $29.00, while our model-based Fair Value estimate is $3.43 — implying the stock looks roughly 88.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte pres…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -83% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +19%

Frequently asked questions

Is Xvivo Perfusion AB (XVIPF) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.43 versus a price of $29.00 — about −88% (overvalued). Model-based estimate, not financial advice.
What is the fair value of XVIPF?
Our 21-model fair value for Xvivo Perfusion AB is $3.43 (as of Jun 25, 2026), built from audited fundamentals. The current price is $29.00.
What is the quality score of XVIPF?
Xvivo Perfusion AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.